#1 Clinical Trials Search in Europe

Plasma

This article explores the use of plasma in various clinical trials, focusing on its applications in treating COVID-19 and managing bleeding during heart surgery. Plasma, a component of blood rich in antibodies and clotting factors, has shown promise in addressing different medical conditions. We’ll examine how researchers are investigating plasma’s potential to save lives and improve patient outcomes across different medical scenarios.

Table of Contents

What is Plasma?

Plasma is a crucial component of blood that plays a vital role in various medical treatments. It is the liquid part of blood that contains important proteins, antibodies, and other substances that can help in treating different medical conditions. Plasma-based treatments have gained significant attention in recent years due to their potential therapeutic benefits[1][2].

Types of Plasma Treatments

There are several types of plasma-based treatments used in medical practice:

  • Plasma-derived Factor VIII (FVIII): This is a treatment used for hemophilia A, a blood clotting disorder. It contains the clotting factor that patients with hemophilia A lack[1].
  • Platelet-Rich Plasma (PRP): This is a concentrated form of plasma that contains a high number of platelets. PRP is used in various treatments, including osteoarthritis and peptic ulcer bleeding[2][4].
  • Convalescent Plasma: This is plasma collected from individuals who have recovered from a specific infection, such as COVID-19. It contains antibodies that may help fight the disease in other patients[3].

Medical Conditions Treated with Plasma

Plasma-based treatments are used for various medical conditions:

  • Hemophilia A: Plasma-derived Factor VIII is used to treat this blood clotting disorder. It helps replace the missing clotting factor in patients, allowing their blood to clot normally[1].
  • Osteoarthritis: Platelet-Rich Plasma (PRP) is being studied for its potential in treating osteoarthritis, particularly in the wrist. The growth factors in PRP may help stimulate cartilage regeneration[2].
  • COVID-19: Convalescent plasma from recovered COVID-19 patients is being investigated as a potential treatment for those with active infections[3].
  • Peptic Ulcer Bleeding: PRP is being studied for its potential to stop bleeding in peptic ulcers, which are sores in the lining of the stomach or small intestine[4].

Preparation and Administration

The preparation and administration of plasma treatments vary depending on the specific type:

  • Plasma-derived Factor VIII: This is typically administered intravenously (through a vein) at a maximum dosage of 50 IU per kilogram of body weight. It may be given 2-3 times per week or as needed during bleeding episodes[1].
  • Platelet-Rich Plasma (PRP): PRP is prepared from the patient’s own blood. The blood is drawn and then processed to concentrate the platelets. For osteoarthritis treatment, it may be injected directly into the affected joint[2].
  • Convalescent Plasma: This is collected from recovered patients and transfused into patients with active infections. In COVID-19 studies, patients typically receive 2-4 units of plasma, with each unit being 200-220 ml[3].

Benefits and Potential Risks

Plasma treatments offer several potential benefits:

  • For hemophilia patients, plasma-derived Factor VIII can help prevent and control bleeding episodes[1].
  • PRP treatments may help reduce pain and improve function in osteoarthritis[2].
  • Convalescent plasma may help fight infections in some patients[3].

However, there are also potential risks to consider:

  • Some patients may develop antibodies (inhibitors) against the treatment, particularly in hemophilia treatment[1].
  • As with any blood product, there’s a small risk of allergic reactions or transmission of infections[3].
  • Specific to plasma transfusions, there are rare risks of complications such as transfusion-associated circulatory overload (TACO) or transfusion-related acute lung injury (TRALI)[3].

Ongoing Research and Future Prospects

Research into plasma-based treatments is ongoing, with several clinical trials underway:

  • Studies are investigating the effectiveness of plasma-derived Factor VIII compared to recombinant Factor VIII in preventing inhibitor development in hemophilia patients[1].
  • The potential of PRP in treating osteoarthritis and other joint conditions is being explored[2].
  • Research is ongoing to determine the efficacy of convalescent plasma in treating COVID-19[3].
  • The use of PRP in treating bleeding peptic ulcers is also under investigation[4].

These ongoing studies aim to provide more evidence on the effectiveness and safety of plasma-based treatments, potentially expanding their use in various medical conditions.

Aspect COVID-19 Trials Heart Surgery Trials
Primary Use of Plasma Treatment of severe COVID-19 infection Management of bleeding during/after surgery
Type of Plasma Convalescent plasma from recovered patients Fresh frozen plasma or prothrombin complex concentrate
Main Outcome Measures Mortality rates, viral load reduction, antibody levels Blood loss, transfusion requirements, hemostasis
Comparison Groups Standard care without plasma Other blood products (e.g., PCC)
Potential Benefits Improved immune response against SARS-CoV-2 Reduced bleeding, fewer transfusions needed
Safety Monitoring Transfusion reactions, TRALI, TACO Thrombotic events, volume overload

FAQ

  • What is convalescent plasma and how is it being used in COVID-19 trials? Convalescent plasma is blood plasma collected from patients who have recovered from COVID-19. It contains antibodies against the virus. In clinical trials, it is being tested as a potential treatment for severe COVID-19 cases, with the hope that the antibodies in the plasma can help fight the infection in critically ill patients.
  • How is plasma being used in heart surgery trials? In heart surgery trials, plasma is being compared to other blood products like prothrombin complex concentrate (PCC) for managing bleeding. Researchers are investigating whether plasma or PCC is more effective in reducing blood loss, decreasing the need for additional blood transfusions, and improving overall outcomes for patients undergoing heart surgery.
  • What are the potential benefits of using plasma in medical treatments? Plasma can provide essential antibodies and clotting factors that may help in fighting infections or managing bleeding. In COVID-19 treatment, it may help boost the immune response. In heart surgery, it can help restore clotting factors and potentially reduce bleeding complications.
  • Are there any risks associated with plasma transfusions? While plasma transfusions are generally considered safe, there are potential risks. These may include allergic reactions, transfusion-associated lung injury (TRALI), transfusion-related circulatory overload (TACO), and rarely, transmission of infections. Clinical trials carefully monitor for these adverse events.
  • How do researchers measure the effectiveness of plasma treatments in clinical trials? Researchers use various measures to assess plasma effectiveness, including mortality rates, length of hospital stay, need for mechanical ventilation, changes in viral load or antibody levels (for COVID-19 trials), amount of blood loss, and need for additional blood products (for heart surgery trials). They also monitor for any adverse events related to the treatment.

Ongoing Clinical Trials on Plasma

  • Study on Coagulation Differences Using Fresh Frozen Plasma and Solvent-Detergent Plasma in Children Undergoing Congenital Heart Surgery

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Convalescent Plasma: Blood plasma collected from individuals who have recovered from an infectious disease, containing antibodies that may help fight the infection in others.
  • Prothrombin Complex Concentrate (PCC): A concentrated form of blood clotting factors used to reverse the effects of blood thinners or treat bleeding in patients with clotting factor deficiencies.
  • Fresh Frozen Plasma (FFP): A blood product made from the liquid portion of whole blood, frozen within hours of collection, and used to treat clotting factor deficiencies.
  • Cardiopulmonary Bypass (CPB): A technique used in heart surgery where a machine temporarily takes over the function of the heart and lungs during the operation.
  • International Normalized Ratio (INR): A standardized measurement of blood clotting time, often used to monitor the effectiveness of blood-thinning medications.
  • Hemostasis: The process which causes bleeding to stop, involving the clotting of blood at the site of an injury while maintaining normal blood flow elsewhere in the circulation.
  • Thrombosis: The formation of a blood clot inside a blood vessel, which can obstruct blood flow.
  • Viremia: The presence of viruses in the bloodstream.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Exposure Days (EDs): In hemophilia treatment, the number of days a patient receives factor replacement therapy.

References

  1. https://clinicaltrials.gov/study/NCT01064284
  2. https://clinicaltrials.gov/study/NCT03164122
  3. https://clinicaltrials.gov/study/NCT04345991
  4. https://clinicaltrials.gov/study/NCT03733171